ALRN 6924

Drug Profile

ALRN 6924

Alternative Names: ALRN6924

Latest Information Update: 09 Jul 2017

Price : $50

At a glance

  • Originator Aileron Therapeutics; Roche
  • Developer Aileron Therapeutics
  • Class Antineoplastics; Peptides
  • Mechanism of Action Proto-oncogene protein c mdm2 inhibitors; Tumour suppressor protein p53 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase II Haematological malignancies; Solid tumours
  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 02 Jun 2017 Interim safety and efficacy data from a phase I trial in Solid tumours and Haematological malignancies presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
  • 18 May 2017 ALRN 6924 receives Orphan Drug status for Acute myeloid leukaemia in USA
  • 09 Sep 2016 Phase-I clinical trials in Acute myeloid leukaemia (Second-line therapy or greater) in USA (IV) (NCT02909972)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top